Indazole Compounds as CCR4 Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases involving the CC-chemokine receptor 4 (CCR4) lack effective small molecule antagonists that can target this receptor specifically, limiting therapeutic options for conditions such as asthma, COPD, and inflammatory disorders.
Innovation Solution
Development of indazole compounds, specifically those of formula (I) and their pharmaceutically acceptable salts, which act as CCR4 receptor antagonists, for use in pharmaceutical compositions and therapies to treat conditions indicated by CCR4 receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for CCR4-related diseases are used, then existing therapeutic options are limited, but no effective small molecule CCR4 receptor antagonists are available
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular structures of indazole compounds (formula I) to optimize CCR4 receptor binding affinity and selectivity. By modifying substituents R1-R5 and their configurations, the invention achieves effective CCR4 antagonism where previous treatments failed, directly addressing the lack of effective small molecule antagonists
2Adaptability or versatility
If specific CCR4 receptor antagonists are developed, then therapeutic options improve, but the complexity of developing novel compounds increases
Solution Approach 1:
The patent segments the CCR4 antagonist development into a systematic framework with core indazole structure (formula I) and variable substituents (R1-R5). This segmentation allows independent optimization of different molecular regions, simplifying the development process while enabling creation of multiple effective antagonists with varying pharmacological properties
Solution Approach 2:
The indazole compound framework of formula (I) serves as a universal scaffold that can address multiple CCR4-related diseases (asthma, COPD, inflammatory disorders) through a single molecular platform. This multi-functionality reduces development complexity by providing a versatile solution applicable to various therapeutic indications
Data Source
AI summary
Indazole compounds (I), processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy related to CCR4 receptor antagonists.